Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves
administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT …

Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …

The ability of IL-2 to expand T cells with maintenance of functional activity has been
translated into the first reproducible effective human cancer immunotherapies. The …

Purpose Vitiligo-like depigmentation in patients with melanoma may be associated with
more favorable clinical outcome. We conducted a systematic review of patients with stage III …

Purpose Adoptive cell transfer, the infusion of large numbers of activated autologous
lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic …

Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) has been
tested in advanced melanoma patients at various centers. We conducted a systematic …

Purpose: Adoptive cell transfer therapy (ACT) based on autologous tumor-infiltrating
lymphocytes (TIL) has achieved impressive clinical results in several phase I and II trials …

Lack or loss of tumor antigenicity represents one of the key mechanisms of immune escape
and resistance to T cell–based immunotherapies. Evidence suggests that activation of …

Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells
or T cells genetically engineered to express tumor recognizing receptors has emerged as a …